Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models

Translational Research

Volumn 148, Issue 6, 2006, Pages 309-314

  Hou, Guoqing ^a   Dick, Robert ^a   Zeng, Chunhua ^a   Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; DOXORUBICIN; TETRATHIOMOLYBDIC ACID; ZINC; ZINC CARBONATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; HEART INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TUMOR; TUMOR MODEL;

EID: 33845308841     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.06.005     Document Type: Article

References (23)

1. Cox C., Merajver S.D., Yoo S., Dick R.D., Brewer G.J., Lee J.S., et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 129 (2003) 781-785
2. Cox C.D., Teknos T.N., Barrios M., Brewer G.J., Dick R.D., and Merajver S.D. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 111 4 Pt 1 (2001) 696-701
3. Kent M.S., Madewell B.R., Dank G., Dick R.B., Merajver S.D., and Brewer G.J. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: a pilot study in a canine animal mode. J Trace Elem Exp Med 17 (2004) 9-20
4. Khan M.K., Miller M.W., Taylor J., Gill N.K., Dick R.D., van Golen K., et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4 (2002) 164-170
5. Pan Q., Bao L.W., Kleer C.G., Brewer G.J., and Merajver S.D. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2 (2003) 617-622
6. Pan Q., Kleer C.G., van Golen K.L., Irani J., Bottema K.M., Bias C., et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62 (2002) 4854-4859
7. van Golen K.L., Bao L., Brewer G.J., Pienta K.J., Kamradt J.M., Livant D.L., et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 4 (2002) 373-379
8. Hou G., Dick R., Abrams G.D., and Brewer G.J. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146 (2005) 299-303
9. Brewer G.J., Ullenbruch M.R., Dick R.B., Olivarez L., and Phan S.H. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141 (2003) 210-216
10. Brewer G.J., Dick R., Ullenbruch M.R., Jin H., and Phan S.H. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98 (2004) 2160-2167
11. Askari F.K., Dick R.B., Mao M., and Brewer G.J. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med 229 (2004) 857-863
12. Ma S., Hou G., Dick R.D., and Brewer G.J. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 4 (2004) 419-426
13. Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., Wicha M., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6 (2000) 1-10
14. Redman B.G., Esper P., Pan Q., Dunn R.L., Hussain H.K., Chenevert T., et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9 (2003) 1666-1672
15. Brewer G.J. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 7 (2003) 11-20
16. Brewer G.J. Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic and antiinflammatory effects. Semin Integr Med 1 (2003) 181-190
17. Brewer G.J., Dick R.D., Johnson V.D., Brunberg J.A., Kluin K.J., and Fink J.K. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 132 (1998) 264-278
18. Brewer G.J. Novel therapeutic approaches to the treatment of Wilson's disease. Expert Opin Pharmacother 7 (2006) 317-324
19. Marcellini M., Di Ciommo V., Callea F., Devito R., Comparcola D., Sartorelli M.R., et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med 145 (2005) 139-143
20. Brewer G.J., Dick R.D., Yuzbasiyan-Gurkan V., Tankanow R., Young A.B., and Kluin K.J. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48 (1991) 42-47
21. Yuzbasiyan-Gurkan V., Grider A., Nostrant T., Cousins R.J., and Brewer G.J. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 120 (1992) 380-386
22. Satoh M., Naganuma A., and Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci 67 (2000) 627-634
23. Naganuma A., Satoh M., and Imura N. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn J Cancer Res 79 (1988) 406-411